Tejara Capital Ltd Buys 43,082 Shares of Roivant Sciences Ltd. $ROIV

Tejara Capital Ltd boosted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 9.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 506,095 shares of the company’s stock after acquiring an additional 43,082 shares during the quarter. Roivant Sciences comprises about 4.0% of Tejara Capital Ltd’s holdings, making the stock its 7th largest holding. Tejara Capital Ltd owned approximately 0.07% of Roivant Sciences worth $7,657,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ROIV. Perceptive Advisors LLC purchased a new position in shares of Roivant Sciences in the second quarter valued at $37,546,000. Orbimed Advisors LLC acquired a new position in Roivant Sciences in the 2nd quarter worth $31,324,000. Rubric Capital Management LP lifted its holdings in Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock worth $229,574,000 after buying an additional 2,603,260 shares in the last quarter. Squarepoint Ops LLC boosted its position in Roivant Sciences by 2,580.0% in the 2nd quarter. Squarepoint Ops LLC now owns 2,211,675 shares of the company’s stock valued at $24,926,000 after buying an additional 2,129,150 shares during the last quarter. Finally, Candriam S.C.A. grew its stake in shares of Roivant Sciences by 5,399.5% during the second quarter. Candriam S.C.A. now owns 1,503,994 shares of the company’s stock valued at $16,951,000 after acquiring an additional 1,476,646 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Citigroup lifted their price objective on Roivant Sciences from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Leerink Partners upped their target price on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. HC Wainwright raised their price target on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, The Goldman Sachs Group lifted their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $25.19.

Insider Activity

In other Roivant Sciences news, insider Mayukh Sukhatme sold 1,018,995 shares of the stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $21.71, for a total transaction of $22,122,381.45. Following the sale, the insider directly owned 20,267,429 shares of the company’s stock, valued at approximately $440,005,883.59. This represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $21.92, for a total transaction of $4,384,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at $36,268,766.24. This trade represents a 10.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,332,392 shares of company stock valued at $266,393,645 over the last quarter. 10.80% of the stock is owned by company insiders.

Roivant Sciences Trading Down 1.8%

Shares of ROIV opened at $21.62 on Friday. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $23.91. The firm has a market cap of $15.04 billion, a price-to-earnings ratio of -38.61 and a beta of 1.22. The stock has a 50 day moving average of $21.89 and a 200-day moving average of $17.43.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.